found that elevated levels of synaptic binding protein-like 4 (SYTL4), a Rab effector in vesicular transport, are associated with poor prognostic outcomes in TNBC (triple negative breast cancer, referring to breast cancer lacking estrogen receptor (ESr or Er), progesterone receptor (Pr) expression with lack of epidermal growth factor receptor-2 gene (HER) expression), especially in paclitaxel treated TNBC. The gene discussed is SYTL4; the disease is triple-negative breast carcinoma.